Peroxisome proliferator activated receptor-γ (PPAR-γ) ligands and angiogenesis

被引：90

作者：

A. Margeli

G. Kouraklis

S. Theocharis

机构：

[1] Department of Clinical Biochemistry, Aghia Sophia Children's Hospital, Athens

[2] Department of Surgery, Medical School, University of Athens, Athens

[3] Dept. of Forensic Med. and Toxicol., Medical School, University of Athens, Athens

[4] Zografou, 157 72 Athens, 21, Thessalias Street

来源：

Angiogenesis | 2003年 / 6卷 / 3期

关键词：

Angiogenesis; Cancer; PPAR-γ ligands;

D O I：

10.1023/B:AGEN.0000021377.13669.c0

中图分类号：

学科分类号：

摘要：

The peroxisome proliferator activated receptor (PPAR)-γ ligands have been initially described as important regulators of adipogenic differentiation and glucose homeostasis. Detailed studies in different tissues pointed to the roles of these ligands in cell proliferation and cancer, establishing their anticancer properties against a wide variety of neoplastic cells. The growth of any solid tumor depends on angiogenesis, as tumor vascularization is a vital process for tumor volume increase and its metastatic potential. Recently, the role of PPAR-γ ligands as potent angiogenesis modulators in vitro and in vivo, has been referred. This review takes into consideration the latest data concerning the participation of PPAR-γ ligands in the biological mechanisms underlying angiogenesis inhibition (important in anticancer therapy) and the controversy concerning angiogenesis induction (important in non-neoplastic diseases). As inhibition of angiogenesis represents one of the more promising, new approaches to anticancer therapy, PPAR-γ ligands in addition to their established role as tumor cell cycle modulators could be implicated in future strategies for cancer treatment.

引用

页码：165 / 169

页数：4

共 25 条

[1]

Folkman J., Angiogenesis in cancer, vascular, rheumatoid and other diseases, Nat Med, 1, pp. 27-31, (1995)

[2]

Kahn J., Mehraban F., Ingle G., Et al., Gene expression profiling in an in vitro model of angiogenesis, Am J Pathol, 156, pp. 1887-1900, (2000)

[3]

Yamakawa K., Hosoi M., Koyama H., Et al., Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells, Biochem Biophys Res Commun, 271, pp. 571-574, (2000)

[4]

Hayes A.J., Li L.Y., Lippman M.E., Antivascular therapy: A new approach to cancer treatment, BMJ, 318, pp. 853-856, (1999)

[5]

Benjamin L., Golijanin D., Itin A., Et al., Selective ablation of immature blood vessels in established tumours follows vascular endothelial growth factor withdrawal, J Clin Invest, 103, pp. 159-165, (1999)

[6]

Gelman L., Fruchart J.-C., Auwerx J., An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer, Cell Mol Life Sci, 55, pp. 932-943, (1999)

[7]

Debril M.-B., Renaud J.-P., Fajas L., Auwerx J., The pleiotropic functions of peroxisome proliferator-activated receptor γ, J Mol Med, 79, pp. 30-47, (2001)

[8]

Theocharis S., Margeli A., Kouraklis G., PPAR-gamma ligands as potent antineoplastic agents, Curr Med Chem Anticancer Agents, 3, pp. 239-251, (2003)

[9]

Asano A., Irie Y., Saito M., Isoform-specific regulation of vascular endothelial growth factor (VEGF) family mRNA expression in cultured mouse brown adipocytes, Mol Cell Endocrinol, 174, pp. 71-76, (2001)

[10]

Xin X., Yang S., Kowalski J., Gerritsen M.E., Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo, J Biol Chem, 274, pp. 9116-9121, (1999)

← 1 2 3 →